NCT04635566View on ClinicalTrials.gov

Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2020

Conditions
IncontinenceUrinary IncontinenceUrinary Bladder Cancer
Interventions
DRUG

mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.

mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.

DRUG

Placebo

Placebo one time/day at the evening.

Trial Locations (1)

35516

Urology and Nephrology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04635566 - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute | Biotech Hunter | Biotech Hunter